|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Oklahoma |
|---|---|
| Collaborator: |
Genentech |
| Information provided by: | University of Oklahoma |
| ClinicalTrials.gov Identifier: | NCT00511992 |
Purpose
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Advanced Ovarian Carcinoma Primary Peritoneal Carcinoma Ovarian Carcinosarcoma |
Drug: Avastin |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase II Study of Paclitaxel, Intraperitoneal Cisplatin and IV Bevacizumab Followed by Bevacizumab Consolidation for Advanced Ovarian and Peritoneal Carcinoma |
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2007 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Initial Treatment:
Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles, Cisplatin 75mg/m2 IP Day 2 every 21 days x 6 cycles, Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)
Consolidation Treatment:
Avastin 15mg/kg IV every 21 days x 12 cycles
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States. The high death rate stems from late presentation and tumor that has spread beyond the ovary at the time of diagnoses.
Ovarian cancer typically spreads throughout the peritoneal cavity. Three randomized clinical trial have recently demonstrated the superiority of intraperitoneal(IP) over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer. The success of Bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in advanced ovarian cancer. Based on the mechanism of action of Bevacizumab, there may be benefit of extended therapy with this agent.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Oklahoma | |
| University of Oklahoma Health Sciences Center | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| Principal Investigator: | D. Scott McMeekin, MD | University of Oklahoma |
More Information
| Responsible Party: | University of Oklahoma Health Sciences Center ( D. Scott McMeekin/Section Chief ) |
| Study ID Numbers: | AVF3953 McMeekin |
| Study First Received: | August 3, 2007 |
| Last Updated: | February 6, 2009 |
| ClinicalTrials.gov Identifier: | NCT00511992 History of Changes |
| Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
|
Ovarian Cancer Gynecologic Cancer Ovarian Carcinoma Peritoneal Carcinoma |
IP chemotherapy Intraperitoneal Avastin Bevacizumab |
|
Antineoplastic Agents Gonadal Disorders Physiological Effects of Drugs Urogenital Neoplasms Ovarian Diseases Bevacizumab Genital Diseases, Female Neoplasms, Connective and Soft Tissue Neoplasms by Site Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors Endocrine Gland Neoplasms Neoplasms by Histologic Type |
Ovarian Neoplasms Growth Substances Genital Neoplasms, Female Endocrine System Diseases Angiogenesis Inhibitors Pharmacologic Actions Adnexal Diseases Carcinoma Neoplasms Sarcoma Neoplasms, Complex and Mixed Neoplasms, Glandular and Epithelial Carcinosarcoma |
